Physicochemical Properties
| Molecular Formula | C14H18CL2N4 |
| Molecular Weight | 313.23 |
| CAS # | 2995277-02-4 |
| Related CAS # | Imiquimod;99011-02-6 |
| Synonyms | R 837 dihydrochloride |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vivo | Lmiquimod (IMQ) can be used to induce a psoriasis model[5]. Induced psoriasis model[5] Pathogenic mechanism Lmiquimod (IMQ) can induce inflamed scaly skin lesions similar to plaque psoriasis. IMQ induces epidermal expression of IL-23, IL-17A and IL-17F, as well as an increase in splenic Th17 cells. Specific modeling method: Mice: BALB/c • Male • 8 weeks old Dosage method: 3.125 mg/day • Topical application to the skin • 6 days Note Modeling success indicators Histological changes: The induced mouse back skin begins to show signs of erythema, scaling and thickening. It causes excessive proliferation of keratinocytes and disrupts epidermal differentiation (parakeratosis). Related products: / Antagonist products: / |
| References |
[1]. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858. [2]. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6(6):554-60. [3]. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86(19):10338-46. [4]. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126(6):1338-47. [5]. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009, 182, 9. [6]. Molecular and histopathological profiling of imiquimod induced dermatosis in Swiss Wistar rats: contribution to the rat model for novel anti-psoriasis treatments. Mol Biol Rep. 2021, 48, 5. [7]. Development and Optimization of Imiquimod-Loaded Nanostructured Lipid Carriers Using a Hybrid Design of Experiments Approach. Int J Nanomedicine. 2023.
|
Solubility Data
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1925 mL | 15.9627 mL | 31.9254 mL | |
| 5 mM | 0.6385 mL | 3.1925 mL | 6.3851 mL | |
| 10 mM | 0.3193 mL | 1.5963 mL | 3.1925 mL |